10-Q quarterly report · filed Nov 12, 2026

Generate Biomedicines Inc (GENB) Q3 2026 10-Q Quarterly Report

Short answer

Generate Biomedicines Inc (GENB) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M with net income of −$88M.

Q3 2026 key financials · XBRL

Revenue
$4M
−33.2% QoQ
Net income
−$88M
−30.3% QoQ
Operating margin
-2168.4%
EPS (diluted)
−$0.68
−100.0% QoQ

Source: XBRL data from the Generate Biomedicines Inc (GENB) Q3 2026 10-Q on SEC EDGAR. USD.

Generate Biomedicines Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $4.2M, down $5.4M from $9.6M YoY, as Novartis and Amgen obligations near completion
  • Net loss $87.7M vs $60.0M YoY, operating margin -2,168.4% vs -651.7% YoY
  • GB-0895 highest-spending program, R&D costs $37.1M vs $12.4M YoY; discovery programs lowest at $3.2M vs $10.2M
  • Operating cash outflow $193.2M, investing outflow $170.3M, financing inflow $381.8M, including IPO proceeds
  • Cash, equivalents and marketable securities $404.2M, funding expected into first half of 2028 including Zealand’s $30.0M upfront payment

Risk Factors

  • No material-change statement, but 2026 filing adds Zealand collaboration: $30.0 million upfront payment extends funding into first half of 2028
  • Regulatory risk: EU AI Act provisions effective August 2, 2026, imposing data quality, transparency, monitoring and oversight obligations
  • Clinical risk: GB-0895 Phase 3 severe-asthma trials use one 300 mg dose despite FDA and EMA dose-ranging recommendations
  • Operational risk: GB-0895 transition to autoinjector and pre-filled syringe may require bridging studies or repeat trials
  • Financial risk: Nine-month net loss $216.6 million and accumulated deficit $892.7 million as of September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.